|
Vertical Divider
|
Malignant Hyperthermiais a pharmacogenetic disease of skeletal muscle that may precipitate a potentially fatal sequence of metabolic responses in the presence of triggering anesthetics. The primary triggers for MH are - Inhalational Anesthetics and Succinylcholine.
Incidence estimated at 1:10,000 and 1: 150,000. Etiology involves the uncontrollable release of intramyoplasmic calcium (Ca2+) that results in sustained muscle contractures, which in return produces a hypermetabolic response. The hypermetabolic response manifests as hypercarbia, hyperthermia, tachycardia, and if not treated early, a mixed metabolic and respiratory acidosis, muscle rigidity, severe rhabdomyolysis, circulatory shock and possibly death. NEW MH POLICY Updated FEB 2019:
(incorporates Ryanodex - a new dantrolene formulation) |
Vertical Divider
|
The Cart is stored behind the Fish Bowl Nursing Desk in the F5 Main OR
|